Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.

Ustekinumab yields sustained clinical benefit in systemic lupus erythematosus

17 Jan 2020

Use of ustekinumab in the treatment of systemic lupus erythematosus (SLE) leads to significant improvements in many of the efficacy indices evaluated, with lower risk of flares and sustained response rates, when compared with placebo, according to 1-year data from a phase II trial.

A total of 102 SLE patients were randomized to receive placebo (n=42) or ustekinumab (n=60) in addition to standard-of-care therapy. The active drug was given at ~6 mg/kg single intravenous infusion at week 0, then 90 mg subcutaneous injections every 8 weeks beginning at week 8. At week 24, patients in the placebo group crossed over to subcutaneous ustekinumab 90 mg every 8 weeks, and those who initially received ustekinumab continued therapy through week 40.

The population had a female predominance (placebo, 83.3 percent; ustekinumab, 96.7 percent), and the mean age was 42.9 years in the placebo group and 40.0 years in the ustekinumab group. Median disease duration was 10 years, with four patients in each treatment group having SLE for <1 year. The most common standard-of-care therapy used at baseline was glucocorticoids (placebo, 80.9 percent; ustekinumab, 85.0 percent).

Results of week-24 primary endpoint analysis showed that SLE Responder Index 4 response rates were much higher in the ustekinumab vs placebo group (62 percent vs 33 percent; p=0.006) and maintained through week 48 in the former (63.3 percent).

Among ustekinumab-treated patients, the improvements observed in several disease measures were sustained through week 48. Response rates across efficacy measures also increased among placebo patients who crossed over to ustekinumab (n=33).

Ustekinumab had a safety profile consistent with previous reports for other indications. At least one adverse event (AE) occurred in 81.7 percent of all ustekinumab‐treated patients, while serious AEs were reported in 15.1 percent. There were no documented deaths, malignancies, opportunistic infections or tuberculosis cases.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.